BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Average Recommendation of “Moderate Buy” by Analysts

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) has earned an average rating of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $22.8750.

BBOT has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $25.00 target price on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday. JPMorgan Chase & Co. reduced their price target on shares of BridgeBio Oncology Therapeutics from $25.00 to $23.00 and set an “overweight” rating on the stock in a research report on Friday. UBS Group downgraded shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. Stifel Nicolaus lowered their price objective on shares of BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Leerink Partners cut their price objective on BridgeBio Oncology Therapeutics to $27.00 and set an “outperform” rating on the stock in a research report on Thursday.

BridgeBio Oncology Therapeutics Stock Down 10.3%

Shares of BridgeBio Oncology Therapeutics stock opened at $4.95 on Friday. The business has a 50 day moving average of $8.66 and a 200 day moving average of $8.67. BridgeBio Oncology Therapeutics has a 52 week low of $4.90 and a 52 week high of $14.87. The company has a market cap of $396.84 million, a PE ratio of -1.79 and a beta of 0.38.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($705.20) earnings per share for the quarter. On average, research analysts anticipate that BridgeBio Oncology Therapeutics will post -2.79 earnings per share for the current year.

Key Stories Impacting BridgeBio Oncology Therapeutics

Here are the key news stories impacting BridgeBio Oncology Therapeutics this week:

• Positive Sentiment: JPMorgan maintained an “overweight” rating while lowering its price target from $25 to $23. Even after the reduction, the target implies substantial potential upside from the recent $4.95 share price. JPMorgan price target update
• Positive Sentiment: Wedbush reiterated its “outperform” rating, signaling that it continues to see meaningful value in BridgeBio Oncology Therapeutics despite the recent selloff. Wedbush reiterates outperform rating
• Neutral Sentiment: The company is narrowing its KRAS strategy. BridgeBio Oncology Therapeutics is focusing its development efforts on a more targeted subset of KRAS-related cancer opportunities. The approach could improve capital allocation and differentiation, but it also increases dependence on a narrower group of clinical programs. BridgeBio Oncology Therapeutics bets on a narrower KRAS strategy
• Negative Sentiment: Analyst downgrades drove renewed selling. Leerink Partners issued a pessimistic forecast, while Wall Street Zen lowered the stock to “strong sell.” These actions have weakened investor sentiment toward the company’s valuation and clinical prospects. Leerink Partners forecast Wall Street Zen strong sell downgrade
• Negative Sentiment: BBOT reached a new 52-week low following the downgrades, reinforcing technical and momentum concerns. The stock’s decline of more than 10% in the recent session occurred alongside unusually heavy trading volume. BridgeBio Oncology Therapeutics new 52-week low Why BBOT stock declined

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Hedge funds have recently made changes to their positions in the company. Opaleye Management Inc. lifted its position in BridgeBio Oncology Therapeutics by 1,213.8% during the second quarter. Opaleye Management Inc. now owns 700,000 shares of the company’s stock valued at $5,334,000 after buying an additional 646,718 shares during the period. Granahan Investment Management LLC bought a new position in shares of BridgeBio Oncology Therapeutics in the 1st quarter worth about $2,068,000. Catalio Capital Management LP bought a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter worth about $5,142,000. Armistice Capital LLC lifted its position in BridgeBio Oncology Therapeutics by 142.7% during the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after acquiring an additional 588,000 shares during the period. Finally, BIT Capital GmbH purchased a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at about $313,000. 54.89% of the stock is currently owned by institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.